NO178889C - [(Arylalkylpiperidin-4-yl)metylÅ-2a,3,4,5-tetrahydro-1(2H)-acenaftylen-1-oner og beslektede forbindelser - Google Patents
[(Arylalkylpiperidin-4-yl)metylÅ-2a,3,4,5-tetrahydro-1(2H)-acenaftylen-1-oner og beslektede forbindelserInfo
- Publication number
- NO178889C NO178889C NO922223A NO922223A NO178889C NO 178889 C NO178889 C NO 178889C NO 922223 A NO922223 A NO 922223A NO 922223 A NO922223 A NO 922223A NO 178889 C NO178889 C NO 178889C
- Authority
- NO
- Norway
- Prior art keywords
- loweralkoxy
- hydrogen
- arylalkylpiperidin
- acenaphthylen
- methyla
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- JBXIOAKUBCTDES-UHFFFAOYSA-N 2h-acenaphthylen-1-one Chemical compound C1=CC(C(=O)C2)=C3C2=CC=CC3=C1 JBXIOAKUBCTDES-UHFFFAOYSA-N 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 230000001713 cholinergic effect Effects 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000007074 memory dysfunction Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Lubricants (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/713,249 US5106856A (en) | 1991-06-07 | 1991-06-07 | [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| NO922223D0 NO922223D0 (no) | 1992-06-05 |
| NO922223L NO922223L (no) | 1992-12-08 |
| NO178889B NO178889B (no) | 1996-03-18 |
| NO178889C true NO178889C (no) | 1996-06-26 |
Family
ID=24865395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO922223A NO178889C (no) | 1991-06-07 | 1992-06-05 | [(Arylalkylpiperidin-4-yl)metylÅ-2a,3,4,5-tetrahydro-1(2H)-acenaftylen-1-oner og beslektede forbindelser |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5106856A (no) |
| EP (1) | EP0517221B1 (no) |
| JP (1) | JP2961013B2 (no) |
| KR (1) | KR100234445B1 (no) |
| AT (1) | ATE131814T1 (no) |
| AU (1) | AU646784B2 (no) |
| CA (1) | CA2070714A1 (no) |
| CZ (1) | CZ284591B6 (no) |
| DE (1) | DE69206889T2 (no) |
| DK (1) | DK0517221T3 (no) |
| ES (1) | ES2081517T3 (no) |
| FI (1) | FI101297B1 (no) |
| GR (1) | GR3018558T3 (no) |
| HU (1) | HU217967B (no) |
| IE (1) | IE72199B1 (no) |
| IL (1) | IL102118A (no) |
| MX (1) | MX9202736A (no) |
| NO (1) | NO178889C (no) |
| NZ (1) | NZ243013A (no) |
| PL (1) | PL169423B1 (no) |
| RU (1) | RU2043989C1 (no) |
| TW (1) | TW206214B (no) |
| ZA (1) | ZA924109B (no) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW248556B (no) * | 1993-01-18 | 1995-06-01 | Takeda Pharm Industry Co | |
| US6939879B2 (en) * | 1998-08-28 | 2005-09-06 | Aventis Pharmaceuticals Inc. | Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia |
| EP1891954A3 (en) | 1998-09-30 | 2009-01-14 | Takeda Pharmaceutical Company Limited | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder |
| CA2789014C (en) * | 2010-02-09 | 2019-01-15 | Michela Gallagher | Methods and compositions for improving cognitive function |
| EA027840B1 (ru) | 2010-11-15 | 2017-09-29 | Эйджинбайо, Инк. | Производные пиридазина, композиции и способы лечения когнитивного нарушения |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| CA2904767C (en) | 2013-03-15 | 2022-06-21 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| EP2968237A4 (en) | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION |
| MX391314B (es) | 2013-12-20 | 2025-03-21 | Agenebio Inc | Derivados de benzodiazepina, composiciones, y metodos para tratar el deterioro cognitivo. |
| US10925834B2 (en) | 2015-05-22 | 2021-02-23 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| MX392119B (es) | 2015-06-19 | 2025-03-11 | Agenebio Inc | Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo |
| US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| EA202190076A1 (ru) | 2018-06-19 | 2021-09-22 | Эйджинбайо, Инк. | Производные бензодиазепина, композиции и способы лечения когнитивных нарушений |
| CN120584115A (zh) | 2022-08-19 | 2025-09-02 | 艾吉因生物股份有限公司 | 苯并氮杂䓬衍生物、组合物和用于治疗认知损害的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2589934A (en) * | 1950-08-24 | 1952-03-18 | Abbott Lab | 2-aminomethyl-tetrahydroacenapthones-1 and their preparation |
| US3391178A (en) * | 1964-12-30 | 1968-07-02 | Ernest E. Campaigne | Dialkylaminoalkyl 1-oxo-2alpha, 3, 4, 5-tetrahydroacenaphthen-2alpha-carboxylates |
| FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| JP2969359B2 (ja) * | 1989-01-13 | 1999-11-02 | 武田薬品工業株式会社 | 環状アミン化合物 |
-
1991
- 1991-06-07 US US07/713,249 patent/US5106856A/en not_active Expired - Fee Related
-
1992
- 1992-05-23 TW TW081104034A patent/TW206214B/zh active
- 1992-06-04 FI FI922592A patent/FI101297B1/fi not_active IP Right Cessation
- 1992-06-04 EP EP92109467A patent/EP0517221B1/en not_active Expired - Lifetime
- 1992-06-04 DE DE69206889T patent/DE69206889T2/de not_active Expired - Fee Related
- 1992-06-04 ES ES92109467T patent/ES2081517T3/es not_active Expired - Lifetime
- 1992-06-04 NZ NZ243013A patent/NZ243013A/en unknown
- 1992-06-04 DK DK92109467.8T patent/DK0517221T3/da active
- 1992-06-04 AT AT92109467T patent/ATE131814T1/de not_active IP Right Cessation
- 1992-06-05 ZA ZA924109A patent/ZA924109B/xx unknown
- 1992-06-05 CZ CS921713A patent/CZ284591B6/cs not_active IP Right Cessation
- 1992-06-05 AU AU18015/92A patent/AU646784B2/en not_active Ceased
- 1992-06-05 HU HU9201887A patent/HU217967B/hu not_active IP Right Cessation
- 1992-06-05 IL IL10211892A patent/IL102118A/en not_active IP Right Cessation
- 1992-06-05 PL PL92294803A patent/PL169423B1/pl unknown
- 1992-06-05 JP JP4144694A patent/JP2961013B2/ja not_active Expired - Fee Related
- 1992-06-05 KR KR1019920009765A patent/KR100234445B1/ko not_active Expired - Fee Related
- 1992-06-05 NO NO922223A patent/NO178889C/no not_active IP Right Cessation
- 1992-06-06 RU SU925052251A patent/RU2043989C1/ru active
- 1992-06-08 MX MX9202736A patent/MX9202736A/es not_active IP Right Cessation
- 1992-06-08 CA CA002070714A patent/CA2070714A1/en not_active Abandoned
- 1992-07-01 IE IE921840A patent/IE72199B1/en not_active IP Right Cessation
-
1995
- 1995-12-28 GR GR950403690T patent/GR3018558T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO178889C (no) | [(Arylalkylpiperidin-4-yl)metylÅ-2a,3,4,5-tetrahydro-1(2H)-acenaftylen-1-oner og beslektede forbindelser | |
| DK0477903T3 (da) | Substituerede 4-amino-3-pyridinoler, fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler | |
| NO921490D0 (no) | 1-(pyrido(3,4-b)-1,4-oksazinyl-4-yl)-1h-indoler, mellomprodukter og fremgangsmaate for fremstilling derav samt anvendelse som medikamenter | |
| NZ222640A (en) | Quinolinol derivatives and pharmaceutical compositions | |
| FI896243A0 (fi) | N-pyridinyl-9h-karbazol-9-aminer, foerfarande foer deras framstaellning och deras anvaendning som laekemedel. | |
| NO902813D0 (no) | (1,2,3,4-tetrahydro-9-acridinimino)cykloheksankarboksylsyre og relaterte forbindelser, fremgangsmaate for fremstilling og anvendelse som medikamenter. | |
| DK0570850T3 (da) | Benzo(b)thiophen-3-yl-piperaziner, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler | |
| NO902556D0 (no) | 4,5,5a,6-tetrahydro-3h-isoksazol(5,4,3-kl)akridinderivater og fremgangsmaate for fremstilling derav. | |
| MX9100638A (es) | 1-(piridinilalquil)-1h-indoles,indolinas y compuestos analogos afines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |
Free format text: LAPSED IN DECEMBER 2000 |